Epidemiology and Real-World Treatment of Chronic Graft-Versus-Host Disease Post Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis

Home / Intelligence / Scientific Publications / Epidemiology and Real-World Treatment of Chronic Graft-Versus-Host Disease Post Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis

Chronic Graft-Versus-Host Disease (cGVHD) is a complication of hematopoietic cell transplantation (HCT). While the clinical outcomes of cGVHD are well documented, few studies have assessed its treatment practices in the real-world. The objectives of this study are to quantify the prevalence of cGVHD, to examine provider prescribing patterns, and to evaluate the healthcare cost and resource utilization (HCRU) in a real-world US cGVHD population.

Authors

Carlos Bachier, Sanjay Aggarwal, Kalin Hennegan, Andrew Milgroom, Kevin Francis, Marcello Rotta

Journal

Blood; American Society of Hematology

View publication

Related Intelligence

Scientific Publications

ISPOR EU 2024 Research Posters

RWD8 Maximizing the Value of Real-World Data in HEOR – a Comparative Assessment of Claims and Emr Sources in Europe Authors: Diehl M, Saikumar S, Furrer DE, Kulkarni A, Patel N, Hadker N Abstract: OBJECTIVES: Heterogeneity in the European RWD landscape, both regionally and across vendors, requires fit-for-purpose dataset selection in HEOR studies. Visibility into […]

Scientific Publications

ISPOR US 2024 Research Posters

Healthcare Resource Utilization of Patients with Short Bowel Syndrome Dependent on Parenteral Support: A Retrospective Claims Analysis AUTHOR(S): Ali A1, Micic D2, Gallivan M1, Kulkarni A3, Henderson J4, Mitchell G4 1Trinity Life Sciences, Waltham, MA, USA, 2University of Chicago Medical Center, Gastroenterology, Hepatology, and Nutrition, Chicago, IL, USA, 3Trinity Life Sciences, Malden, MA, USA, 4VectivBio AG, Basel, Basel, Switzerland […]

Scientific Publications

ISPOR EU 2023 Research Posters

Implications of the Implementation of the Joint Committee Assessment on Launch Planning for Medical Technologies in Europe Acosta Luis S1, O’Hara M2, Yeh M2 1Trinity Partners, LLC, London, UK, 2Trinity Life Sciences, Waltham, MA, USA The EU-wide Joint Clinical Assessment (JCA) is set to be operational from January 2025. The Trinity team reviewed the available literature […]